lestaurtinib has been researched along with dcc-2036 in 2 studies
| Studies (lestaurtinib) | Trials (lestaurtinib) | Recent Studies (post-2010) (lestaurtinib) | Studies (dcc-2036) | Trials (dcc-2036) | Recent Studies (post-2010) (dcc-2036) |
|---|---|---|---|---|---|
| 124 | 12 | 63 | 31 | 1 | 30 |
| Protein | Taxonomy | lestaurtinib (IC50) | dcc-2036 (IC50) |
|---|---|---|---|
| Chain A, Tyrosine-protein kinase ABL1 | Homo sapiens (human) | 0.0024 | |
| Chain A, Tyrosine-protein kinase ABL1 | Homo sapiens (human) | 0.0024 | |
| Chain A, Tyrosine-protein kinase ABL1 | Homo sapiens (human) | 0.0024 | |
| Tyrosine-protein kinase ABL1 | Homo sapiens (human) | 0.0022 | |
| High affinity nerve growth factor receptor | Homo sapiens (human) | 0.0055 | |
| Tyrosine-protein kinase Yes | Homo sapiens (human) | 0.002 | |
| Receptor-type tyrosine-protein kinase FLT3 | Homo sapiens (human) | 0.002 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
| Abdel-Aziz, AK; Abouzid, KAM; Dokla, EME; McPhillie, MJ; Milik, SN; Minucci, S | 1 |
2 other study(ies) available for lestaurtinib and dcc-2036
| Article | Year |
|---|---|
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
Discovery of a benzimidazole-based dual FLT3/TrKA inhibitor targeting acute myeloid leukemia.
Topics: Antineoplastic Agents; Apoptosis; Benzimidazoles; Cell Line; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; fms-Like Tyrosine Kinase 3; Humans; Models, Molecular; Molecular Structure; Protein Kinase Inhibitors; Receptor, trkA; Structure-Activity Relationship | 2022 |